Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)

This grant funds efficacy studies in established rare disease preclinical models, including pharmacodynamic and pharmacokinetic work, to show a therapeutic agent merits further development. It supports small molecules, biologics, or biotechnology-derived products, aiming to advance projects toward investment for IND applications or clinical trial progression.